Charting The Slow-Growing Psoriatic Arthritis Market

Market Snapshot: Despite the availability of anti-TNF biosimilars, the global market for drugs for psoriatic arthritis will grow to $4.1bn in 2025 due to the entry of new branded drugs at high prices in the US, according to a new Datamonitor Healthcare forecast report.

snail showing slow growth

The US FDA's recent approvals of Pfizer Inc.'s JAK inhibitor Xeljanz, Eli Lilly & Co.'s IL-17A inhibitor Taltz and Johnson & Johnson's infused anti-TNF Simponi Aria for psoriatic arthritis brings three more products into a crowded space already dominated by mainstay TNF blockers, which are beginning to face biosimilars competition.

The FDA approved a new indication on Dec. 14 for Xeljanz (tofacitinib), given orally twice daily or in a once-daily formulation (Xeljanz XR) for patients with active psoriatic arthritis (PsA) who have not had an adequate response to methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By 

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.